Abstract

You have accessJournal of UrologyModerated Poster, Monday, May 22, 2006, 1:00 - 3:00 pm1 Apr 2006854: RM2 Antigen (Beta 1,4-Galnac-Disialyl-LC4) as a New Serum Marker for Prostate Cancer Seiichi Saito, Seıjı Ueno, Akihiro Ito, Kenji Numahata, Masanori Kato, Shigeto Ishidoya, Takenobu Taima, Yasuko Murayama, Makoto Satoh, Mareyuki Endoh, and Yoichi Arai Seiichi SaitoSeiichi Saito More articles by this author , Seıjı UenoSeıjı Ueno More articles by this author , Akihiro ItoAkihiro Ito More articles by this author , Kenji NumahataKenji Numahata More articles by this author , Masanori KatoMasanori Kato More articles by this author , Shigeto IshidoyaShigeto Ishidoya More articles by this author , Takenobu TaimaTakenobu Taima More articles by this author , Yasuko MurayamaYasuko Murayama More articles by this author , Makoto SatohMakoto Satoh More articles by this author , Mareyuki EndohMareyuki Endoh More articles by this author , and Yoichi AraiYoichi Arai More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(18)33090-8AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "854: RM2 Antigen (Beta 1,4-Galnac-Disialyl-LC4) as a New Serum Marker for Prostate Cancer." The Journal of Urology, 175(4S), pp. 275–276 © 2016 by American Urological AssociationFiguresReferencesRelatedDetails Volume 175Issue 4SApril 2006Page: 275-276 Advertisement Copyright & Permissions© 2016 by American Urological AssociationMetricsAuthor Information Seiichi Saito More articles by this author Seıjı Ueno More articles by this author Akihiro Ito More articles by this author Kenji Numahata More articles by this author Masanori Kato More articles by this author Shigeto Ishidoya More articles by this author Takenobu Taima More articles by this author Yasuko Murayama More articles by this author Makoto Satoh More articles by this author Mareyuki Endoh More articles by this author Yoichi Arai More articles by this author Expand All Advertisement Loading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call